BiologicalDrug
Aldesleukin clinical trials
Also written Proleukin.
- studies test it
- 184
- open now
- 17
- in phase 3
- 18
- first study started
- 1991
Keep track of what changes. Save the aldesleukin studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
170 studies that test it; most in 2015 (12); 1 more planned to start later
| Year | Studies |
|---|---|
| 1991 | 1 |
| 1992 | 1 |
| 1995 | 5 |
| 1996 | 4 |
| 1997 | 6 |
| 1998 | 7 |
| 1999 | 1 |
| 2000 | 5 |
| 2001 | 7 |
| 2002 | 6 |
| 2003 | 1 |
| 2004 | 4 |
| 2005 | 10 |
| 2006 | 5 |
| 2007 | 5 |
| 2008 | 8 |
| 2009 | 4 |
| 2010 | 2 |
| 2011 | 5 |
| 2012 | 6 |
| 2013 | 7 |
| 2014 | 8 |
| 2015 | 12 |
| 2016 | 2 |
| 2017 | 10 |
| 2018 | 4 |
| 2019 | 7 |
| 2020 | 4 |
| 2021 | 4 |
| 2022 | 6 |
| 2023 | 2 |
| 2024 | 4 |
| 2025 | 3 |
| 2026 | 4 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 3
- Phase 1
- 87
- Phase 2
- 113
- Phase 3
- 18
- Phase 4
- 3
- No phase
- 3
What it is tested for
Each study’s main condition, where its own words name it.
- Melanoma
- 36
Who runs them
Industry 12 · Other 172
National Cancer Institute (NCI) (39) · National Institute of Allergy and Infectious Diseases (NIAID) (13) · Fred Hutchinson Cancer Center (11) · M.D. Anderson Cancer Center (9) · Assistance Publique - Hôpitaux de Paris (8) · Masonic Cancer Center, University of Minnesota (6) · Chiron Corporation (5) · Jonsson Comprehensive Cancer Center (4)
Often tested with
Tested in the same studies.
Cyclophosphamide (33) · Fludarabine (25) · Fludarabine phosphate (12) · Low-dose Aldesleukin ILT-101 (8) · Sargramostim (7) · Interleukin-2 (7) · Dinutuximab (5) · Busulfan (5)
Studies
Open first, then newest update. How each study uses aldesleukin is read from its arms, and is right about nine times in ten.
Testing it · 184
- Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic MalignanciesRecruitingPhase 1National Cancer Institute (NCI)NCT06904066Written as aldesleukin
- T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung CancerRecruitingPhase 2National Cancer Institute (NCI)NCT02133196Written as Aldesleukin
- Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing CancersRecruitingPhase 1/2National Cancer Institute (NCI)NCT02830724Written as Aldesleukin
- Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell CarcinomaRecruitingPhase 2National Cancer Institute (NCI)NCT05155033Written as Aldesleukin
- Autologous Tumor Infiltrating Lymphocytes With Interleukin-2 for the Treatment of Locally Advanced, Recurrent or Metastatic Gastrointestinal Stromal TumorsNot yet recruitingPhase 2Joal BeaneNCT07647068Written as Aldesleukin
- Ciclosporin Followed by Low-dose IL-2 in Patients With Recently Diagnosed Type 1 DiabetesRecruitingPhase 2Assistance Publique - Hôpitaux de ParisNCT05153070Written as ILT101
- Low Dose IL-2 for the Treatment of Crohn's DiseaseRecruitingPhase 1/2Boston Children's HospitalNCT04263831Written as Interleukin-2 (aldesleukin).
- Study Evaluating a Gene Therapy for IPEX Syndrome Through the Expression of FOXP3 on Deficient T Cells to Produce Tregs-like.Not yet recruitingPhase 1/2Assistance Publique - Hôpitaux de ParisNCT07697118Written as ILT-101
- A Phase II Trial of Tumour Infiltrating Lymphocyte Adoptive Cell Therapy in Patients With Immune Checkpoint Inhibitor Resistant Unresectable or Metastatic MelanomaNot yet recruitingPhase 2East Metropolitan Health Service, AustraliaNCT07651618Written as Aldesleukin
- Use of Low Doses of Interleukin-2 in Autism Spectrum DisordersNot yet recruitingPhase 2Assistance Publique - Hôpitaux de ParisNCT07589842Written as ILT-101 ld-(IL2)
- Low-Dose Interleukin-2 and Pembrolizumab for the Treatment of Stage IV Non-Small Cell Lung CancerRecruitingEarly Phase 1Emory UniversityNCT05493566Written as Aldesleukin
- Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic CancersRecruitingPhase 1/2Hadassah Medical OrganizationNCT05296564Written as Aldesleukin
- Adding IL-2 to Tebentafusp to Eradicate Cancer ProgressionRecruitingPhase 1/2St Vincent's Hospital, SydneyNCT07063875Written as Aldesleukin
- IL-2 Plus Abatacept in FTDRecruitingPhase 1The Methodist Hospital Research InstituteNCT06395038Written as Abatacept plus Aldesleukin
- Thymalfasin and Recombinant Human IL-2 Injections in Treating Lymphocytopenia for Patients With Malignant Hematological TumorsRecruitingPhase 2The First Affiliated Hospital of Xiamen UniversityNCT06584006Written as Recombinant Human Interleukin-2 Injections
- Immunotherapy for the Treatment of Advanced Solid TumorRecruitingPhase 1/2Tongji HospitalNCT03658785Written as Aldesleukin
- High Risk Neuroblastoma Study 1.8 of SIOP-Europe (SIOPEN)RecruitingPhase 3St. Anna KinderkrebsforschungNCT01704716Written as Aldesleukin
- Phase I Study of Cellular Immunotherapy for Recurrent/Refractory Malignant Glioma Using Intratumoral Infusions of GRm13Z40-2, An Allogeneic CD8+ Cytolitic T-Cell Line Genetically Modified to Express the IL 13-Zetakine and HyTK and to be Resistant to Glucocorticoids, in Combination With Interleukin-2CompletedPhase 1City of Hope Medical CenterNCT01082926Written as aldesleukin
- Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic CancerActive, not recruitingPhase 1National Cancer Institute (NCI)NCT06253520Written as Aldesleukin
- Genetically Modified T-Cells Followed by Aldesleukin in Treating Patients With Stage III-IV MelanomaActive, not recruitingPhase 1M.D. Anderson Cancer CenterNCT01955460Written as Aldesleukin
See all 184 studies that test aldesleukin →
Given in every arm · 70 — aldesleukin is usual care beside what is tested
- Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic CancerRecruitingPhase 2National Cancer Institute (NCI)NCT01174121Written as Aldesleukin
- Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic CancerRecruitingPhase 2National Cancer Institute (NCI)NCT03412877Written as Aldesleukin
- A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple MyelomaRecruitingPhase 1/2AstraZenecaNCT07681596Written as Aldesleukin
- A Study Evaluating the Immunotherapy Treatment for Ovarian Cancer and Other Advanced Malignancies.RecruitingPhase 1/2University of ChicagoNCT07389239Written as Aldesleukin
- E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated CancersRecruitingPhase 1/2Christian HinrichsNCT05639972Written as Aldesleukin
- Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic CancerRecruitingPhase 1/2Aulos Bioscience, Inc.NCT05267626Written as Aldesleukin
- KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung CancerRecruitingPhase 1Christian HinrichsNCT05483491Written as Aldesleukin
- Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 PatientsRecruitingPhase 1/2National Cancer Institute (NCI)NCT03190941Written as Aldesleukin
- A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of PembrolizumabRecruitingPhase 2National Cancer Institute (NCI)NCT02621021Written as Aldesleukin
- E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated CancersRecruitingPhase 2Christian HinrichsNCT05686226Written as Aldesleukin
- A2-ESO-1 TCR-Engineered T Cells for Relapsed/Refractory Advanced or Metastatic NY-ESO-1 Overexpression Positive Triple Negative Breast CancerRecruitingPhase 1University of Southern CaliforniaNCT05989828Written as Aldesleukin
- To Evaluate the Safety and Efficacy of ADP-TILIL7 in Patients With Locally Advanced or Metastatic MelanomaRecruitingPhase 1Inge Marie SvaneNCT06204991Written as Proleukin
- TBio-4101 and Pembro wi/ or w/o Chemo in Recurrent/Metastatic HNSCCCompletedPhase 1H. Lee Moffitt Cancer Center and Research InstituteNCT06236425Written as Aldesleukin
- Phase 1/2a Study of ICT01 Plus Low Dose SC IL-2 in Patients With Advanced Solid TumorsTerminatedPhase 1/2ImCheck Therapeutics, an Ipsen companyNCT05307874Written as Proleukin Injectable Product
- LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue SarcomasActive, not recruitingPhase 2M.D. Anderson Cancer CenterNCT03449108Written as Aldesleukin
- Genetically Modified T Cells and Decitabine in Treating Patients With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube CancerActive, not recruitingPhase 1Roswell Park Cancer InstituteNCT03017131Written as Aldesleukin
- E7 TCR T Cells for Human Papillomavirus-Associated CancersCompletedPhase 1/2National Cancer Institute (NCI)NCT02858310Written as Aldesleukin
- A Study of Metastatic Gastrointestinal Cancers Treated With Tumor Infiltrating Lymphocytes in Which the Gene Encoding the Intracellular Immune Checkpoint CISH Is Inhibited Using CRISPR Genetic EngineeringCompletedPhase 1/2Intima Bioscience, Inc.NCT04426669Written as Aldesleukin
- CISH Inactivated TILs in the Treatment of NSCLCWithdrawnPhase 1/2Intima Bioscience, Inc.NCT05566223Written as Aldesleukin
- Prospective Randomized Study of Cell Transfer Therapy for Metastatic Melanoma Using Tumor Infiltrating Lymphocytes Plus IL-2 Following Non-Myeloablative Lymphocyte Depleting Chemo Regimen Alone or in Conjunction With 12Gy Total Body Irradiation (TBI...CompletedPhase 2National Cancer Institute (NCI)NCT01319565Written as Aldesleukin
Showing 20 of 70.
As the comparator · 2 — what is tested is compared with aldesleukin
- Safety and Effectiveness of MPCD Therapy on the Treatment of Malignant Pleural EffusionStatus unknownNot applicablePeking Union Medical CollegeNCT04131231Written as recombinant human interleukin-2(rhIL-2)
- Prospective Randomized Comparative Study of Cell Transfer Therapy Using CD8+-Enriched Short-Term Cultured Anti-Tumor Autologous Lymphocytes Following a Non-Myeloablative Lymphocyte Depleting Chemotherapy Regimen Compared to High-Dose Aldesleukin in M...CompletedPhase 2National Cancer Institute (NCI)NCT01118091Written as Aldesleukin
Codes
What other systems call aldesleukin · ClinicalTrials.gg INT003745
- MeSH (NLM) C082598aldesleukinConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) M89N0Q7EQRALDESLEUKINConfirmed FDA, NLM, Wikidata
- RxNorm 70223Confirmed FDA, Wikidata
- Wikidata Q20801763aldesleukinConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C1498AldesleukinOne source FDA
- DrugBank DB00041One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C082598 | aldesleukin | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | M89N0Q7EQR | ALDESLEUKIN | Confirmed FDA, NLM, Wikidata |
| RxNorm | 70223 | — | Confirmed FDA, Wikidata |
| Wikidata | Q20801763 | aldesleukin | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C1498 | Aldesleukin | One source FDA |
| DrugBank | DB00041 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.